- Home
- GH vs JKHY Comparison
GH vs JKHY Comparison
Compare GH & JKHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | JKHY |
|---|---|---|
| Founded | 2011 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 13.4B |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GH | JKHY |
|---|---|---|
| Price | $91.48 | $153.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 12 |
| Target Price | $119.79 | ★ $197.25 |
| AVG Volume (30 Days) | ★ 2.1M | 782.8K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.58% |
| EPS Growth | 6.74 | ★ 19.31 |
| EPS | N/A | ★ 3.70 |
| Revenue | $982,021,000.00 | ★ $1,536,603,000.00 |
| Revenue This Year | $33.30 | $8.03 |
| Revenue Next Year | $28.27 | $6.39 |
| P/E Ratio | ★ N/A | $41.65 |
| Revenue Growth | ★ 32.88 | 7.37 |
| 52 Week Low | $36.36 | $144.13 |
| 52 Week High | $120.74 | $193.39 |
Technical Indicators
Market Signals| Indicator | GH | JKHY |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 41.84 |
| Support Level | $89.32 | $145.85 |
| Resistance Level | $101.77 | $161.27 |
| Average True Range (ATR) | 5.54 | 3.58 |
| MACD | 0.65 | 0.22 |
| Stochastic Oscillator | 69.78 | 46.95 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.